NCT00005851 - Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

July 31, 2004

Study Completion Date

September 27, 2018

Conditions

Recurrent Renal Cell CancerStage IV Renal Cell Cancer

Interventions

DRUG

fludarabine phosphate

Given IV

RADIATION

total-body irradiation

Undergo TBI

PROCEDURE

nonmyeloablative allogeneic hematopoietic stem cell transplantation

Undergo nonmyeloablative allogeneic PBSC transplantation

DRUG

cyclosporine

Given PO or IV

DRUG

mycophenolate mofetil

Given PO or IV

PROCEDURE

peripheral blood stem cell transplantation

Undergo nonmyeloablative allogeneic PBSC transplantation

BIOLOGICAL

therapeutic allogeneic lymphocytes

Undergo DLI

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (6)

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

75246

Baylor University Medical Center, Dallas

80012

Rocky Mountain Cancer Centers-Aurora, Aurora

85724

University of Arizona Health Sciences Center, Tucson

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER